If the FTC can make its case that the core claims in support of medical transitioning were bogus, the consequences both in America and abroad would be noting less than monumental.
The FTC launched a suit against World Professional Association for Transgender Health (WPATH) this week.
The press release opens with the basic details…
The Federal Trade Commission, along with Alaska, Iowa, Nebraska and Texas, today filed a lawsuit against the World Professional Association for Transgender Health (WPATH), alleging the organization has provided the means for medical providers to make false and unsubstantiated claims to parents in order to sell pediatric medical transition services.
WPATH, an association of clinicians who profit from pediatric medical transition services, recommended medical interventions, including drugs and surgery, for children and adolescents who expressed dissatisfaction with or distress about their sex traits. In their complaint, the FTC and its state partners allege that these recommendations misled parents and children about the medical consensus and medical necessity, as well as the safety and effectiveness, of such services, in violation of the FTC Act.
“Today, the FTC filed a lawsuit against WPATH alleging that the organization made false and unsubstantiated claims regarding the necessity, effectiveness and safety of puberty blockers, hormones and sex-change surgeries,” said Chairman Andrew N. Ferguson. “Children, but especially their parents, must have complete and truthful information when making decisions to purchase medical services. For decades, the FTC has taken action against entities that make deceptive and unsubstantiated health-related claims. The complaint filed today reflects that same long-standing mandate: when an entity makes a claim about a medical treatment, the claim must be truthful, evidence-based and not misleading.”
In 2022, WPATH omitted all mention of age limitations for breast amputation or penis removal from the “Standards of Care” document providing the organization’s official recommendations for treating sex-trait-related dissatisfaction or distress in children. As alleged in the complaint, WPATH did not base this decision on medical evidence. [bold type was added to key phrases]
The suit further alleges that information about side effects of these medical interventions were not disclosed to the patients. The entire point of patient consent rests on the understanding that — in view of the trade-offs between benefits and hazards of any given procedure, is whether the medical intervention under consideration is worth the risk.
That’s the ‘news’ part of this story. What are the possible implications?
We’ve all heard the trans activists’ rationale that it’s ‘better to have a live daughter or a dead son’. That was the argument that shocked many parents into silence when they might otherwise have objected to their children undergoing such a radical procedure.
If the FTC is able to prove their allegations, it will undercut the entire rational under which many parents were bullied into compliance. It would mean hthat manipulative catchphrase wasn’t merely overstated, but it was not founded on any credible studies at all.
It has been previously claimed that WPATH and other closely-aligned activist parties didn’t actually present clinical evidence in support of their above-mentioned claims, but they worked cooperatively with other groups to amplify their own arguments in justifying the various elements of what came to be collectively known as ‘gender-affirming care’.
The National Library of Medicine itself highlights disputed claims and circular reasoning touching on some of the core claims associated with transgender issues, and official criticisms of bias in WPATH’s methodology go back at least as far as 2019 in the ‘Canadian Gender Report’ article entitled Bias, not evidence dominates WPATH transgender standard of care.
Interesting to note, the 2019 WPATH study on bias, referenced an earlier, 2011 study explaining the conflict-of-interest risks inherent in medical research more broadly.That study has an interesting nugget that would have given us a whole different way of looking at lab coat credibility and objectivity.
All 12 included studies reported financial relationships between guideline authors and the pharmaceutical industry. In addition, a review of the development process of Lyme disease guidelines by the Infectious Diseases Society of America reported relationships between guideline authors and developers of Lyme disease diagnostic test kits and vaccines as well as insurance companies reviewing disability claims related to Lyme disease — NIH
Knowing what we now know about Fauci’s CIA connections, that might have given us a whole different way of looking at what was REALLY driving the official pandemic response.
This case won’t just impact America. Countries all around the world genuflected to WPATH claims about gender and treatment. If they are shown to have been corrupt, their counterparts around the world would likely fall with them.
As would many policies they helped generate. And psychologists would be next up to bat, in explaining how we got here in the first place, if even the protocols governing clinical practices themselves appear to be based on unproven assertions.
